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View and review
The utility of omega-3 
fatty acids in epilepsy
More than just a farmed tilapia!
Vera C. Terra1, Ricardo M. Arida2, Guilherme M. Rabello3, 
Esper A. Cavalheiro3, Fulvio A. Scorza3
ABSTRACT
The epilepsies are one of the most common serious brain disorders and 20 to 30% of 
people developing epilepsy continue to have seizures and are refractory to treatment 
with the currently available therapies. Approximately one in a 1000 patients with chronic 
epilepsy will die suddenly, unexpectedly, and without explanation, even with post-mortem 
examination and this phenomenon is called sudden unexplained death in epilepsy (SUDEP). 
Understanding the mechanisms underlying SUDEP may lead to the identification of 
previously unrecognized risk factors that are more amenable to correction. We discuss 
here the possible implications of omega-3 fatty acids consumption on SUDEP prevention.
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RESUMO
As epilepsias encontram-se entre as mais sérias doenças neurológicas; 20 a 30% dos 
pacientes com epilepsia continuam apresentando crises e são refratários as terapias 
disponíveis atualmente. Aproximadamente um em cada 1000 pacientes com epilepsia 
crônica irá morrer de forma súbita, não esperada e sem explicação, mesmo com o exame 
pós-morte. Este fenômeno é denominado morte súbita e inesperada em epilepsia 
(SUDEP). Compreender os mecanismos envolvidos nos casos de SUDEP pode levar 
à identificação de fatores ainda não reconhecidos e passíveis de serem corrigidos. 
Discutiremos a seguir as possíveis implicações do consumo do ácido graxo ômega-3 na 
prevenção dos casos de SUDEP.
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The epilepsies are one of the most 
common serious brain disorders and it 
knows no age, racial, social class, geo-
graphic, or national boundaries1. Several 
studies have reported that approximately 
50 million people worldwide have epilep-
sy and that between 70 and 80% of people 
developing epilepsy will go into remission, 
while the remaining patients continue to 
have seizures and are refractory to treat-
ment with the currently available thera-
pies2,3. Furthermore, 80% of the 50 million 
people who have epilepsy live in countries 
with poor resources and this apparent dis-
crepancy between rich and poor countries 
could be due by higher mortality in people 
with epilepsy in the developing world than 
in more affluent countries4,5. In this con-
text, it has been described that each year 
about one in a 1000 patients with chron-
ic epilepsy will die suddenly, unexpectedly, 
and without explanation, even with post-
mortem examination6. In the vernacular 
of the world of epilepsy, this phenomenon 
is called sudden unexplained death in ep-
ilepsy (SUDEP)6. Actually, epilepsy is as-
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sociated with a two- to three-fold increase in mortality 
compared to the general population, and SUDEP is the 
most important direct epilepsy-related cause of death7. 
To date, a number of associated factors for SUDEP have 
been assessed in a number of studies but the results are 
not wholly consistent between them8,9. These include re-
fractoriness of the epilepsy, presence of generalized ton-
ic-clonic seizures, polytherapy with antiepileptic drugs, 
young age, duration of the seizure disorder ranging from 
15 to 20 years, early onset of epilepsy and winter temper-
atures9,10. Additionally, knowledge of risk factors under-
lying SUDEP could guide investigations into its patho-
physiologic mechanisms11. Conversely, understanding the 
mechanisms underlying SUDEP may lead to the identi-
fication of previously unrecognized risk factors that are 
more amenable to correction11. Although different mech-
anisms play a role in different cases, there are indications 
that cardiac arrhythmia during and between seizures play 
a potential pathomechanism for SUDEP9,12. Thus, consid-
ering that efforts to prevent and control seizures should 
be directed towards removing the causes of SUDEP13, 
several experimental and clinical studies have been clear-
ly demonstrated that complementary medical therapies, 
especially omega-3 fatty acids, are often tried by patients 
with epilepsy to control their seizures and hence SUDEP. 
In brief, the first randomized trial of omega-3 supplemen-
tation in patients with chronic epilepsy were encourag-
ing, demonstrating a transient effect on seizure control 
that was not confirmed by other research group, but ad-
ditional trials are required14,15. Although these results did 
not totally confirm that omega-3 fatty acids supplemen-
tation reduce the frequency of epileptic seizures in pa-
tients with refractory epilepsy; they established the safe-
ty of omega-3 supplementation in people with epilepsy15.
Polyunsaturated fatty acids (PUFAs) docosahexaeno-
ic acid (DHA, 22: 6n-3) are major components of mem-
brane phospholipids in brain tissue16. The eicosanoids 
play important roles in neural function including sleep in-
duction, long term potentiation, spatial learning and syn-
aptic plasticity, resolution of inflammation (lipoxins) and 
anti-inflammatory and neuroprotective bioactivity (di-
hydroxy-docosatriene, neuroprotectin D1, formed from 
DHA)17. Diets deficient in omega 3 PUFA lead to reduced 
DHA in the brain and increased turnover of arachidon-
ic acid to eicosanoids, an effect which is overcome by re-
storing the omega 3 PUFA to the diet17.
Studies in mice reported that both omega-3 and ome-
ga-6 fatty acids protect cells from oxidative stress and 
suppress apoptosis and PUFA supplementation may have 
neuroprotective effects18. Also, it has been demonstrat-
ed that n-3 PUFA treatment increased BDNF protein lev-
els in the motor cortex of mice19, enhances hippocampal 
neurogenesis, with an increase in the number of prolifer-
ating neurons and density of dendritic spines of CA1 py-
ramidal neurons in the hippocampus20.
Similarly, studies had demonstrated that DHA re-
duced expressions of tumor necrosis factor-alpha, inter-
leukin-6, nitric oxide synthase, and cyclo-oxygenase-2, in-
duced by interferon-gamma, and induced upregulation of 
heme oxygenase-1 in microglia21.
Using the pilocarpine model of epilepsy, a valuable 
tool to study the pathogenesis of temporal lobe epilepsy 
in human condition, our research group was the first to 
demonstrate that chronic treatment with omega-3 pro-
motes neuroprotection and positive plastic changes in the 
brain of rats with epilepsy22, with a decreased in neuro-
nal death in CA1 and CA3 subfields of the hippocampus. 
This could be attributed to n-3 PUFAs ion channel mod-
ulation23-25, and anti-inflammatory action.
In in vitro studies, DHA has been reported to inhib-
it epileptiform activity and synaptic transmission mainly 
through the frequency-dependent blockade of Na+ chan-
nels in the rat hippocampus23, and to stabilize neuronal 
membrane by suppressing voltage-gated Ca2+ currents26 
and Na+ channels24.
After these research evidences of beneficial effects of 
omega-3 fatty acids in the brain and clinical reports of 
transitory seizure control patients with epilepsy should 
be encourage to eat fish more frequently. The associa-
tion between fish consumption and low rates risk of car-
diovascular disease has been studied nearly four decades 
ago with the consumption of seafood diets by Greenland 
Eskimos, Alaskan Natives and Japanese people residing 
in fishing villages27-30. Recently, several noncardiovascu-
lar actions of fish consumption have also been described, 
suggesting that a regular diet of fish could be of benefit 
in many conditions31, including various central nervous 
system (CNS) diseases32,33. Concerning CNS, we need to 
keep in mind that omega-3 fatty acids (from fatty fish in 
the human diet) also appear effective on the structure, the 
biochemistry, the physiology and thus the function of the 
brain34,35. As we know, the brain is one of the organs with 
the highest level of lipids (fats). Brain lipids, formed of fat-
ty acids, participate in the structure of membranes, for in-
stance 50% fatty acids are polyunsaturated in the gray mat-
ter, 1/3 are of the omega-3 family, and are thus of dietary 
origin36. Thus, seafood (commonly found in fish and fish 
oil) is the only foods that provide large amounts of ome-
ga-331,32,36. Fish can be classified into lean fish that store lip-
id in the liver (eg, cod) or “fatty” (“oily”) fish that store lip-
id in the flesh (eg, salmon, tuna, sardines and herring)31. 
On the other hand, it is very important to emphasise that 
some types of fish may contain high levels of methylmer-
cury, PCBs (polychlorinated biphenyls), dioxins and oth-
er environmental contaminants32,37-39. Levels of these sub-
stances are generally highest in older, larger and predato-
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ry fish32,37-39. So, as the concentration of methylmercury is 
increased in predatory fish, the best seafood choices are 
those with nonpredatory characteristics. Anchovies, At-
lantic herring, salmon, sardines, and trout have low lev-
els of methylmercury, whereas tuna, shark, tilefish, and 
swordfish have high levels of methylmercury32,37-39. A 
study developed by researchers from Wake Forest Uni-
versity School of Medicine characterized the content of 
favorable and unfavorable polyunsaturated fatty acids 
(omega-3 and omega-6) found in commonly eaten fish, 
with closer inspection on the four most commonly con-
sumed farmed fish (salmon, trout, tilapia and catfish)40. Ti-
lapia is now the second (to farmed Atlantic salmon) most 
widely farmed fish in the world40. Based in all these facts, 
what we, as neuroscientists, should be thinking about it? 
Firstly and most important, the health benefits of the 
omega-3 in fish have been well documented40,41. Concern-
ing CNS and associated disorders, the belief that “fish is 
brain food” has been held around the world for well over 
two thousand years33,42,43. Actually, it is clear that fish sup-
plies omega-3 oils, essential for brain and eye tissue de-
velopment in infants; it remains fundamental to those tis-
sues throughout life33,42. Furthermore, the implications of 
omega-3 deficiency on the brain are profound and span 
the entire human life cycle. Beginning in pregnancy, pre-
mature birth and its potential neurologic complications 
may result from omega-3 deficiency33,42. On the other 
hand, one observation deserves explanation here. After 
much discussion, consensus was reached on the impor-
tance around the balance of omega-6 and omega-3 fatty 
acids for homeostasis and normal development44. Thus, 
the ratio of omega-6 to omega-3 is an important determi-
nant of health44. Anthropological evidence suggests that 
human ancestors evolved on a diet in which the ratio of 
omega-6/omega-3 was about 1, whereas in the Western 
diets, the ratio is 15/1 to 17/144. In these lines, it has been 
extensively demonstrated that excessive amounts of ome-
ga-6 and a very high omega-6/omega-3 ratio, as is found 
in today’s Western diets, is associated with serious phys-
iological dysfunctions and contributes to the develop-
ment of several diseases such as heart attacks, throm-
botic stroke, arrhythmia, arthritis, osteoporosis, inflam-
mation, mood disorders, obesity, and cancer44,45. In this 
context, these excessive amounts of omega-6 fatty acids 
upsetting the balance that was characteristic during evo-
lution when our genes were programmed to respond to 
diet and other aspects of the environment44. This consid-
eration was recently demonstrated in an elegant study 
conducted by Weaver and colleagues that developed a di-
etary intervention strategy in which 27 healthy humans 
were fed a controlled diet mimicking the omega-6/ome-
ga-3 ratios of early humans over 5 weeks46. For that, the 
authors then looked at the gene levels of immune sig-
nals and cytokines that impact autoimmunity and aller-
gy in blood cells. Thus, they found that many key signal-
ing genes that promote inflammation were markedly re-
duced compared to a normal diet, including a signaling 
gene for PI3K protein, a critical early step in autoimmune 
and allergic inflammation responses. With these results, 
the authors demonstrated, for the first time in humans, 
that polyunsaturated fatty acids may exert their clinical 
effects via their capacity to regulate the expression of sig-
nal transduction genes and genes for proinflammatory 
cytokines46. In sum, the importance of omega-3 essen-
tial fatty acids in the diet is now evident47. In order to im-
prove the ratio of omega-6/omega-3, it will be necessary 
to decrease the intake of omega-6 fatty acids from vege-
table oils and meat and to increase the intake of omega-3 
fatty acids by increasing the intake of fish to two to three 
times per week47. Finally, the American Heart Associa-
tion released a scientific statement, “Fish Consumption, 
Fish Oil, Omega-3 Fatty Acids, and Cardiovascular Dis-
ease” on the effects of omega-3 fatty acids on heart func-
tion (including antiarrhythmic effects), hemodynamics 
(cardiac mechanics) and arterial endothelial function48. 
On the whole, there are a great number of evidences 
that omega-3 fatty acids are very important for the nor-
mal functioning of the heart and the brain, while PUFA 
themselves are important in membrane structure and 
function17. The inhibitory effect of DHA on nitric oxide 
production and inflammatory process establishment may 
have a main role in omega-3 fatty acids mechanisms of 
action21. Our research group are totally in agreement with 
Professor Russo that concluded in his elegant study that it 
is really necessary to intensify the scientific efforts in or-
der to clarify many controversial aspects of fish consump-
tion in order to make human diet healthier49.
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